Zealand Pharma completes registration of capital increase

Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increaseNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT...

Søborg, 28/06/2024 (informazione.it - comunicati stampa - salute e benessere)

Company announcement – No. 36 / 2024

– Further to the Company announcements no. 33, 34 and 35 / 2024, Zealand Pharma A/S (" " or the “ ”) (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines for obesity, other metabolic, and certain rare diseases, announces that it has today, as part of completion of a directed issue and private placement (the " "), registered with the Danish Business Authority, the capital increase of approx. DKK 7 billion, divided into 8,350,000 ordinary shares (the " ").

Following the registration of the New Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 71,000,761 divided into 71,000,761 shares with a nominal value of DKK 1 each.

The New Shares rank with Zealand's existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The New Shares have been issued under a temporary ISIN code and are expected to be admitted to trading on Nasdaq Copenhagen on 1 July 2024 in Zealand's permanent ISIN code DK0060257814. The temporary ISIN code is expected to be merged with the permanent ISIN code on 2 July 2024.

The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.

Goldman Sachs International, Jefferies GmbH, Morgan Stanley and Nordea Danmark, Filial af Nordea Bank Abp, Finland, are acting as joint global coordinators and joint bookrunners in the Offering, and Van Lanschot Kempen N.V. is acting as lead manager in the Offering (the joint global coordinators and the lead manager are jointly referred to as the " ").

Plesner and DLA Piper LLP (US) are acting as Danish and U.S. legal advisors respectively to Zealand. Kromann Reumert is acting as legal advisor to the Managers.

Adam Lange, Investor Relations Officer
ALange@zealandpharma.com

Anna Krassowska, Vice President, Investor Relations & Corporate Communications
AKrassowska@zealandpharma.com

Henriette Wennicke, Executive Vice President and Chief Financial Officer
HWennicke@zealandpharma.com

Adam Steensberg, President and Chief Executive Officer
ASteensberg@zealandpharma.com

Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The Company has development partnerships with several pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with presence in the U.S. For more information about Zealand's business and activities, please visit www.zealandpharma.com .